+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tasigna"

Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 128 Pages
  • Global
From
Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2030 - Product Thumbnail Image

Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2030

  • Report
  • December 2021
  • 141 Pages
  • Global
From
Tasigna - API Insight, 2022 - Product Thumbnail Image

Tasigna - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Tasigna Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Tasigna Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • April 2023
  • 77 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Tasigna is a brand of medication used to treat certain types of leukemia, a type of cancer of the blood and bone marrow. It is a tyrosine kinase inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Tasigna is used to treat chronic myeloid leukemia (CML) in adults and children, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults. It is usually taken in combination with other medications. Tasigna is manufactured by Novartis, a Swiss multinational pharmaceutical company. Other companies in the leukemia drug market include Bristol-Myers Squibb, Pfizer, and Celgene. Show Less Read more